Sage/Biogen Depression Data Likely To Prolong Commercial Debate
Data from the Phase III CORAL study of zuranolone showed the drug missing efficacy at day 15, which may dampen its appeal in the real-world setting.
You may also be interested in...
Zurzuvae will launch this year for postpartum depression, but US FDA rejection of the drug in major depressive disorder spurred Sage to cut R&D programs and jobs as it and partner Biogen evaluate next steps in MDD.
CEO Barry Greene and team spoke with Scrip about Sage and Biogen’s focus on short-term, episodic dosing, and said doctors and payers – pending zuranolone’s approval – are responding to the sales pitch.
The companies reported positive Phase III data in postpartum depression, a market opportunity of up to half a million women in the US with a condition that remains underdiagnosed.